Ruella; Marco

Patent Applications and Registrations

Patent applications and USPTO patent grants for Ruella; Marco.The latest application filed is for "cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell".

Company Profile

12.9.25

Ruella; Marco - Ardmore PA
Ruella; Marco - US
Ruella; Marco - Philadelphia PA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Cd20 Therapies, Cd22 Therapies, And Combination Therapies With A Cd19 Chimeric Antigen Receptor (car)- Expressing Cell App 20220195010 - Bitter; Hans ; et al.	2022-06-23
Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias App 20220073639 - RUELLA; Marco ; et al.	2022-03-10
Treatment Of Cancer Using Humanized Anti-bcma Chimeric Antigen Receptor App 20220064316 - Brogdon; Jennifer ; et al.	2022-03-03
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Grant 11,149,076 - Bitter , et al. October 19, 2	2021-10-19
Anti-BCMA chimeric antigen receptor Grant 11,084,880 - Brogdon , et al. August 10, 2	2021-08-10
Combination Therapy With Chimeric Antigen Receptor (car) Therapies App 20210213063 - Isaacs; Randi ; et al.	2021-07-15
Anti-car Compositions And Methods App 20210179709 - Gill; Saar ; et al.	2021-06-17
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain Grant 11,026,976 - Brannetti , et al. June 8, 2	2021-06-08
Treatment Of Cancer Using A Cd123 Chimeric Antigen Receptor App 20210002377 - Brogdon; Jennifer ; et al.	2021-01-07
Methods And Compositions Comprising Cart And A Smac Mimetic App 20200376035 - Ruella; Marco ; et al.	2020-12-03
Treatment of cancer using a CD123 chimeric antigen receptor Grant 10,703,819 - Brogdon , et al.	2020-07-07
CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell Therapy App 20200080056 - RUELLA; Marco ; et al.	2020-03-12
Treatment Of Cancer Using Anti-cd19 Chimeric Antigen Receptor App 20190388471 - June; Carl H. ; et al.	2019-12-26
Treatment And Prevention Of Cytokine Release Syndrome Using A Chimeric Antigen Receptor In Combination With A Kinase Inhibitor App 20190336504 - Gill; Saar ; et al.	2019-11-07
Cd20 Therapies, Cd22 Therapies, And Combination Therapies With A Cd19 Chimeric Antigen Receptor (car)- Expressing Cell App 20190292238 - Bitter; Hans ; et al.	2019-09-26
Treatment of cancer using anti-CD19 Chimeric Antigen Receptor Grant 10,357,514 - June , et al. July 23, 2	2019-07-23
Treatment Of Cancer Using A Chimeric Antigen Receptor In Combination With An Inhibitor Of A Pro-m2 Macrophage Molecule App 20190161542 - Gill; Saar ; et al.	2019-05-30
Treatment Of Cancer Using 5 Humanized Anti-bcma Chimeric Antigen Receptor App 20190153061 - Brogdon; Jennifer ; et al.	2019-05-23
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Grant 10,253,086 - Bitter , et al.	2019-04-09
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Grant 10,174,095 - Brogdon , et al. J	2019-01-08
Treatment Of Cancer Using A Cd123 Chimeric Antigen Receptor App 20180312595 - Brogdon; Jennifer ; et al.	2018-11-01
Combination Of Chimeric Antigen Receptor Therapy And Amino Pyrimidine Derivatives App 20180140602 - Angst; Daniela ; et al.	2018-05-24
Treatment of cancer using a CD123 chimeric antigen receptor Grant 9,815,901 - Brogdon , et al. November 14, 2	2017-11-14
Cd20 Therapies, Cd22 Therapies, And Combination Therapies With A Cd19 Chimeric Antigen Receptor (car)- Expressing Cell App 20160362472 - Bitter; Hans ; et al.	2016-12-15
Treatment Of Cancer Using A Cd123 Chimeric Antigen Receptor App 20160068601 - Brogdon; Jennifer ; et al.	2016-03-10
Treatment Of Cancer Using Humanized Anti-bcma Chimeric Antigen Receptor App 20160046724 - Brogdon; Jennifer ; et al.	2016-02-18
Treatment Of Cancer Using Anti-cd19 Chimeric Antigen Receptor App 20150283178 - June; Carl H. ; et al.	2015-10-08

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.